Abstract 2584
Background
Approximately 20-30% of non-melanoma skin cancers are squamous cell carcinomas of the skin (SCCS). SCCS incidence is increasing and they often occur in elderly or immunosuppressed patients (pts). SCCS can progress to stages impossible to treat by surgical excision or radiotherapy. Cisplatin-based combinations show efficacy but are too toxic for elderly pts. Cetuximab (Ce) demonstrates 69% disease control rate (DCR) at 6 weeks but in few, highly selected pts. This study aims to evaluate the efficacy of Ce in non-selected pts with SCCS.
Methods
This retrospective study included pts with relapsing unresectable or metastatic SCCS treated with Ce monotherapy (weekly loading dose 400 and 250 mg/m²). The primary objective was DCR at 6 weeks. 60 pts (38 male) with local relapses of metastatic CSCC (100%), were treated between 30/05/2007 and 07/04/2017 in 13 centers. Median age was 83.1 yrs (min 47.4, max 96.1 yrs). Two-thirds of pts had one or two comorbidities, including 13% (n = 8) with immune disorder. 54% had local relapse. Main metastatic locations were nodes (n = 15), lung (n = 8) and skin (n = 5). 90% were chemotherapy-naïve, 57% had previous radiotherapy, and all were primarily resected. Mean time between previous treatment and Ce was 20.1 months (min 0, max 300). Mean Ce injection number was 24.8 (min 4, max 60).
Results
Complete response, partial response, stabilization (S) and progression were 7%, 48%, 32% and 13%, respectively, at 6 weeks and 2%, 42%, 29% and 27% at 3 months. 90% of pts experienced at least a disease S as best overall response. Ce was discontinued in 1 patient after first injection due to grade III infusion-related toxicity. All other grade III toxicities were cutaneous (n = 8) with 5 discontinuations. No toxic deaths were reported. Median follow-up, progression-free survival and overall survival were 11.7 months [95% CI: 9.6-30.1], 9.7 months [95% CI: 4.8-43.4] and 17.5 months [95% CI: 9.4-43.1] respectively.
Conclusions
Cetuximab is a safe and efficient treatment for patients, even very old, with SCCS. The toxicity profile of Ce compares very favorably with cisplatine-based protocols. These results indicate that Ce is a promising platform to test new combinations.
Clinical trial identification
Legal entity responsible for the study
Centre Antoine Lacassagne.
Funding
Merck KGaA.
Editorial Acknowledgement
Disclosure
F. Peyrade: Board member: Merck KGaA. All other authors have declared no conflicts of interest.
Resources from the same session
1310 - Lymphocytes express receptor tyrosine kinases in patients with renal cell carcinoma and healthy donors
Presenter: Ilya Tsimafeyeu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1596 - Oncogenes analysis using GO-based clustering
Presenter: Dmitriy Babenko
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5181 - PNU-74654 enhances the antiproliferative effects of 5-FU in breast cancer and antagonizes thrombin induced cell growth via the Wnt Pathway
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3344 - P21 has the potential to become the monitoring marker for the CDK4/6 inhibitors resistance in breast cancer
Presenter: Masafumi Iida
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
894 - Overexpression of NAMPT in adult T-cell leukemia/lymphoma patients and anti-tumor activity of a NAMPT inhibitor in vivo
Presenter: Tomohiro Kozako
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2224 - 9-ING-41, a clinically relevant inhibitor of Glycogen Synthase Kinase-3 (GSK-3), is active pre-clinically in human bladder and renal cell cancers
Presenter: Hiroo Kuroki
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3380 - A new natural compound identified with metabolomic approach has cytotoxic activity against human colorectal cancer cell lines with acquired resistance to cetuximab
Presenter: Vincenzo De Falco
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4713 - Multiple Myeloma Metal Levels and Proteasome Activity
Presenter: Kai Uwe Stumpf
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4134 - A translational drug-screening tool for interrogating the effect of anti-TGF-_ therapy on fibroblast activity and the desmoplastic reaction
Presenter: Neel Nissen
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2736 - Eribulin demonstrate selectively high sensitivity to recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) cells and xenograft tumors
Presenter: hiroko kitahara
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract